Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder
- None.
- None.
Insights
The recent findings from the Phase 2b clinical trial of MM120 for the treatment of generalized anxiety disorder (GAD) are noteworthy due to the high remission rate reported among participants. The designation of MM120 as a breakthrough therapy by the FDA underscores its potential to significantly alter the standard of care for GAD. The data suggests a single 100-microgram dose could lead to long-lasting benefits, which is relatively unprecedented in the field of mental health where ongoing treatment is often necessary.
Current treatment options for GAD include a combination of medication and psychotherapy, but they do not work for all patients and many have to deal with side effects. If MM120 can provide relief with fewer doses and minimal side effects, it could reduce the long-term burden on patients and healthcare systems. However, it's important to remain cautious until long-term safety and efficacy data are available.
The breakthrough therapy designation for MM120 has significant economic implications. Mental health disorders, such as GAD, impose a substantial economic burden due to direct healthcare costs and indirect costs such as reduced productivity. An effective and durable treatment could alleviate some of these costs. Furthermore, the breakthrough designation could expedite the review process, potentially leading to a faster market entry and offering economic benefits to the developer.
However, the cost-effectiveness of MM120 will be a crucial factor in its adoption. The healthcare industry will need to evaluate the pricing of MM120 in relation to its clinical benefits and the current cost of long-term treatments for GAD. Payers and providers will consider the total cost of care, including potential reductions in other healthcare services if MM120 proves to be more effective than existing therapies.
The positive outcomes from the clinical trial and subsequent FDA breakthrough therapy designation for MM120 could have a significant impact on the stock market, particularly in the biotechnology and pharmaceutical sectors. This announcement may lead to increased investor confidence in Numinus and MindMed, potentially affecting their stock prices. The success of Numinus as a top enrolling site demonstrates their capability in clinical trial management, which could attract partnerships with other drug developers, enhancing their business prospects.
Investors will closely monitor the progress of MM120 through subsequent trial phases and regulatory review. The market potential for an innovative GAD treatment is substantial, given the prevalence of the condition. It's essential to assess the competitive landscape, as any new treatment entering the market would compete with established pharmaceuticals and alternative therapies. The long-term impact on the companies involved will depend on MM120's final approval, market penetration and sustained clinical effectiveness.
The research was conducted over 20 clinical trial sites with 198 participants. Numinus' Cedar Clinical Research Draper Utah research clinic was among the highest enrolling sites for the study, with its clinic at
"We were pleased to participate in this trial of MM120, with the results indicating a robust and durable improvement for trial participants with GAD. This is an important development in treating a condition that is considered the second most common mental health condition among American adults," said Dr. Robison. "I particularly commend MindMed for designing a study that removed variables such as additional medications and psychotherapy so the effects of MM120 were isolated and fully evaluated."
"Our experience in operating clinical trials for leading drug developers, along with our collaborative approach, was a factor in our success as top enrolling sites for MindMed," added Payton Nyquvest, Numinus Founder and CEO. "We look forward to continuing to work with MindMed as it advances its important research into MM120. With more novel drug treatments moving through the clinical trial stages with the goal of being approved, Numinus is well-positioned with an infrastructure that includes clinical research, treatment clinics and practitioner training."
Numinus Wellness Inc. (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
Learn more at www.numinus.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.
Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect" and "intend" and statements that an event "may", "will", "should", "could" or "might" occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements, including challenges and uncertainties inherent in product and/or treatment development and in the psychedelics industry generally, availably of suitable subjects, the uncertainties of clinical success, the possibility of adverse events, and the timeline for the availability of the treatment under investigation; the laws, challenges and risks involved in the production of a psychedelics drug; and the uncertainty of the level of demand, uptake and/or insurance coverage for treatment other risks that are set forth in and other risks that are set forth in our annual information form dated November 29, 2023 and available on SEDAR at www.sedarplus.ca. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. Numinus does not undertake any obligation to update forward-looking statements even if circumstances or management's estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.
______________________________ |
View original content to download multimedia:https://www.prnewswire.com/news-releases/numinus-wellness-congratulates-mindmed-on-positive-results-from-phase-2b-clinical-trials-of-mm120-for-generalized-anxiety-disorder-302083590.html
SOURCE Numinus Wellness Inc.
FAQ
What is the significance of the positive data generated from Mind Medicine's Phase 2b clinical trial of MM120 for GAD?
How many participants were involved in the Phase 2b clinical trial of MM120 for GAD?
What designation did the FDA give to MM120 for GAD treatment?
Who were the Principal Investigators in the Phase 2b clinical trial of MM120 for GAD?
Why was Numinus Wellness Inc. recognized as a top enrolling site for the Phase 2b clinical trial of MM120 for GAD?
